APL-5125 / Apollo Therap - LARVOL DELTA

Exploiting the Cryptic αD Pocket of Casein Kinase 2α (CK2α) to Deliver Highly Potent and Selective Type 1 Inhibitors. (PubMed, J Med Chem) - "A drug discovery project to develop a new series of bivalent CK2α inhibitors with increased cell potency and selectivity identified 61f (APL-5125), a highly potent, ATP-competitive CK2α inhibitor with exquisite kinase selectivity and cellular potency. Compound 61f demonstrates in vivo inhibition of p-AKT S129 in tumors (HCT116) following once-daily oral administration and shows a clear PK-PD relationship with unbound drug exposure. 61f has a superior preclinical profile to existing CK2α inhibitors and is currently under evaluation in patients with advanced solid tumors."

Journal • Oncology • Solid Tumor

A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=100 | Recruiting | Sponsor: Apollo Therapeutics Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Appendix Cancer • Biliary Cancer • Breast Cancer • Cholangiocarcinoma • Colorectal Cancer • Endometrial Adenocarcinoma • Endometrial Cancer • Gastric Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Hepatology • Oncology • Ovarian Cancer • Pancreatic Cancer • Prostate Cancer • Solid Tumor • Triple Negative Breast Cancer

A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=100 | Not yet recruiting | Sponsor: Apollo Therapeutics Ltd

Metastases • New P1/2 trial • Appendix Cancer • Biliary Cancer • Breast Cancer • Cholangiocarcinoma • Colorectal Cancer • Endometrial Adenocarcinoma • Endometrial Cancer • Gastric Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Hepatology • Oncology • Ovarian Cancer • Pancreatic Cancer • Prostate Cancer • Solid Tumor • Triple Negative Breast Cancer